AMPA receptor antagonism attenuates MK-801-induced hypermetabolism in the posterior cingulate cortex.
The effect of pretreatment with an AMPA receptor antagonist, NBQX, on MK-801-induced alterations in glucose use was examined using [14C]-2-deoxyglucose autoradiography. NBQX (7 mg/kg) had minimal effect on glucose utilisation in all anatomical regions examined. The intravenous administration of MK-801 (0.2 mg/kg) induced increases in glucose use in the limbic system and cingulate cortex. MK-801 reduced glucose utilisation in the sensory motor and auditory cortices. Pretreatment with NBQX attenuated the MK-801-induced hypermetabolism in the posterior cingulate cortex. The decreases in glucose utilisation induced by MK-801 were not exacerbated by the pretreatment with NBQX. The interaction between NBQX and MK-801 suggests a possible method of attenuating some of the adverse effects of the non-competitive NMDA receptor antagonists in the posterior cingulate cortex.
Patel
T R
TR
Wellcome Surgical Institute and Hugh Fraser Neuroscience Laboratories, University of Glasgow, UK.
McCulloch
J
J
D000818:Animals; D001345:Autoradiography; D001522:Behavior, Animal / Q000187:drug effects; D003847:Deoxyglucose / Q000378:metabolism; D016291:Dizocilpine Maleate / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D006179:Gyrus Cinguli / Q000187:drug effects* / Q000378:metabolism*; D008032:Limbic System / Q000378:metabolism; D008297:Male; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors*; D013239:Stereotyped Behavior; D014018:Tissue Distribution
D011810:Quinoxalines; D018091:Receptors, AMPA; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; D016291:Dizocilpine Maleate; D003847:Deoxyglucose